Celsion Corporation

Biotechnology ResearchUnited States11-50 Employees

Celsion Corporation is a United States-based biotechnology company focused on oncology. It maintains an integrated portfolio that includes chemotherapy and gene-mediated immunotherapies, along with RNA interference approaches intended to enhance the effectiveness of established treatments. Its lead candidate, ThermoDox, is a heat-activated liposomal formulation of doxorubicin under global phase 3 evaluation for primary liver cancer, and GEN-1 combines a DNA plasmid encoding IL-12 with a nanoparticle delivery system in a phase I/II study with chemotherapy for newly diagnosed ovarian cancer. Based in the United States, the company operates with a relatively small to mid-sized workforce. In January 2023, Celsion announced a collaboration with The Wistar Institute, reflecting ongoing external partnerships to advance its immunotherapy and vaccine-focused programs.

Sign up for free to view info

Email Format Employee directory